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Dendritic Cells, Infected with Vesicular Stomatitis
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T

he efficacy of current HIV-1 vaccines needs to be improved. Strong combined CD4⫹ and CD8⫹ T cell immunity is considered desirable. Compelling evidence has
shown that virus-specific CD8⫹ T cells resist SIV in macaques
(1–3). Activated CD8⫹ T cells not only kill virus-infected cells
(4 – 6) but also may reduce HIV-1 spread by releasing antiviral
chemokines (7). For many viruses, specific CD4⫹ T cells are additionally valuable, e.g., for maintaining CD8⫹ memory T cells
(reviewed in Ref. 8).
Dendritic cells (DCs)3 are efficient APCs for initiating immunity
(see refs. 9 and 10 for review). Immature DCs take up Ag in the
periphery, as illustrated by the capacity of skin DCs to capture and
express DNA vaccines (11–13). The DCs then migrate via afferent
lymphatics to lymphoid organs, where processed Ags are presented to T cells. Following maturation, DCs prime Ag-specific
CD4⫹ and CD8⫹ T cells, including T cell memory (14). Given the
many specializations that DCs exhibit to initiate T cell immunity,
such as the expression of abundant MHC-peptide complexes and T
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cell costimulators (15, 16), it would seem important for HIV-1
vaccine design to target this physiologic pathway.
It is well documented that envelope-defective HIV-1, when
pseudotyped with another viral envelope encoded by a distinct
plasmid in the virus-producer cells, undergo only one cycle of
replication. These pseudotyped vectors are easy to prepare and
provide a safe way to deliver all HIV-1 genes other than env into
cells. Page (17) and Landau (18) were the first to describe replication-defective HIV-1 vectors containing deletions in the HIV-1
envelope gene. Several subsequent studies used vesicular stomatitis virus (VSV) G protein (VSV-G)-pseudotyped vectors to transduce dividing and nondividing cells (19 –23). Recently, we used
VSV-pseudotyped HIV-1 to infect mature DCs and found that a
small fraction of the cells undergo a single full round of viral
infection and protein synthesis (24).
Here, we infected monocyte-derived DCs with VSV-pseudotyped
HIV-1 to assess Ag presentation to CD4⫹ and CD8⫹ T cells from
infected individuals. To mimic the delivery of vaccines in vivo, we
delivered the nonreplicating vector to an immature stage of DC development. When the infected DCs were matured to maximize T cell
stimulatory activity, the DCs presented HIV-1 Ags as efficiently as
pox vectors to CD4⫹ and CD8⫹ T cells from HIV-1-infected individuals. The mature DCs greatly expanded CD4⫹ and CD8⫹ IFN-␥secreting cells and induced proliferative responses in enriched CD8⫹
T cells. Therefore, VSV-pseudotyped virus is a readily available, safe
approach for transducing DCs and obtaining strong presentation of
HIV-1 to CD4⫹ and CD8⫹ T cells.

Materials and Methods
Patients
Patients from two different institutions were all on HAART therapy that
was initiated after their CD4⫹ T cell counts began to fall. Blood from
individual patients was studied at least twice, and comparable results were
obtained.
0022-1767/00/$02.00
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Nonreplicating vectors are being considered in HIV-1 vaccine design. However, nonreplicating viruses are typically weak immunogens, leading to efforts to target the vaccine to mature dendritic cells (DCs). We have studied a single-cycle form of HIV-1,
prepared by pseudotyping envelope-defective HIV-1 plasmids with the envelope from vesicular stomatitis virus (VSV) G protein
(VSV-G), to which most humans lack preexisting immunity. The nonreplicating, VSV/HIV-1 efficiently infected the immature
stage of DC development, in this case represented by monocytes cultured with GM-CSF and IL-4. A majority of the cells reverse
transcribed the HIV-1 RNA, and a minority expressed gag protein. The infected populations were further matured with CD40 ligand,
leading to strong stimulation of autologous T cells from HIV-1-infected individuals, but not controls. Enriched CD8ⴙ T cells from 12/12
donors released IFN-␥ (50 –300 enzyme-linked immunospots/200,000 T cells) and proliferated. Macrophages were much less efficient in
expanding HIV-1-responsive T cells, and bulk mononuclear cells responded weakly to VSV/HIV-1. CD4ⴙ T cells from at least half of
the donors showed strong responses to VSV/HIV-1-infected DCs. Presentation to CD8ⴙ T cells, but not to CD4ⴙ, was primarily through
an endogenous pathway, because the responses were markedly reduced if envelope-defective virus particles or reverse transcriptase
inhibitors were added. Therefore, nonreplicating vaccines can be targeted to immature DCs, which upon further maturation induce
combined and robust CD4ⴙ and CD8ⴙ immunity. The Journal of Immunology, 2000, 165: 6620 – 6626.
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or control protein (Protein Science, Meriden, CT) and a monocyte:T cell
ratio of 1:3.

Proliferation assay
Infected and uninfected mature DCs were cultured with syngeneic T cells
in round-bottom wells in 200 l of medium. Generally we added DCs to
105 T cells at a ratio of 1:10 or 1:20 as specified in the figure legends.
Triplicate cultures were seeded in parallel. After 5 days, the wells were
pulsed with 1 Ci of [3H]TdR for 8 h.

Detection of HIV-1 p24 protein
For FACS assays, infected DCs were fixed with 4% paraformaldehyde in
PBS for 30 min on ice. Cells were permeabilized for 15 min in 1% saponin
on ice, stained with anti p24 (clone 183, AIDS Research and Reference
Reagent Program) followed by FITC-labeled anti-mouse Ig (Tago Scientific, Burlingame, CA), and double stained with anti-CD86 PE (PharMingen, San Diego, CA). For Western blotting, cells were lysed in RIPA buffer
and equivalent cell numbers were loaded in 9% acrylamide gels. After
transfer, the nitrocellulose was probed with anti-VSV-G (1.5 g/ml;
Boehringer Mannheim, Indianapolis, IN) or anti-p24 Abs and revealed
with enhanced chemiluminescence (Amersham).

Results
Viruses and infection of cells

Infection of DCs with VSV-pseudotyped HIV-1

We were kindly provided with two envelope plasmids to pseudotype
HIV-1: a VSV-G expression construct pHCMV-G from J. Burns (University of California, San Diego, CA) and a murine leukemia virus env plasmid from D. Landau (Aaron Diamond AIDS Research Center, New York,
NY). An env-defective HIV-1, expressing the green fluorescent protein,
was provided by D. Gabuzda (Dana-Farber, Boston, MA). VSV wild-type
virus was a gift of J. K. Rose (Yale University, New Haven, CT). Recombinant vaccinia and avipox were obtained from Virogenetics Corporation
(Troy, NY) Vaccinia vectors were NYVAC parental vector and vP989:
NYVAC-HIV-1 gag/pol (IIIB). Avipox vectors were ALVAC parental and
vCP300:ALVAC-HIV-1 gp 160; gag/pro; nef/pol CTL. Complementation
of env-defective HIV-1 plasmid with the VSV-G plasmid yielded
pseudotyped virus that could only undergo a single round of infection. To
produce virus, 3 ⫻ 106 293T cells were cotransfected with 20 g/ml of the
env-defective and 5 g/ml VSV-G plasmids using the calcium phosphate
method. Virus particles lacking envelope were produced by transfection of
293T cells with env-defective HIV-1 plasmid only. Virus stocks were prepared by collecting the culture supernatants after 72 h, filtering through
0.45-m Millipore filters (Bedford, MA), and storing in aliquots at ⫺80°C.
Virus stocks were spun down through a 3-ml 25% sucrose cushion at
25,000 rpm for 2 h in SW41 rotor. Viral titers (infectious units) were
quantified in HeLa Magi cells as described by Vodicka et al. (25) and also
by p24 ELISA. Immature DCs were infected for 2 h in cytokine medium
with VSV/HIV-1 at a multiplicity of infection of 2–20 ng p24 Ag, or
103–104 infectious units, per 105 cells. AZT or 3TC (1 M, from the
National Institutes of Health AIDS Reagent Program) were added 1 h before infection and maintained throughout the course of the experiments.
The infected DCs were matured with CD40L-expressing cells or soluble
CD40L and cultured for an additional 4 days to allow the expression of
HIV-1 Ags. As noted previously (24), a fraction of these CD40L-matured
DCs expressed HIV-1 proteins but only after 3– 4 days of culture. A total
of 10 PFU of avipox/cell or 2 PFU of vaccinia/cell were used to infect the
different APCs. Proviral DNA in infected DCs was analyzed as described
(26).

We have previously shown that replication-incompetent VSV/
HIV-1 undergoes a single cycle of viral protein synthesis in a small
fraction of mature DCs (24). To model the immature stage of DC
that exists in peripheral tissues, we examined cells that were generated by culturing blood monocytes with GM-CSF and IL-4 (27–
29). These cells are competent in Ag capture and support infection
with wild-type M-tropic HIV-1 (30), but lack the full costimulatory activities of mature DCs (28, 29).
We used viruses complemented with VSV-G after finding that
these were more infectious then those complemented with murine
leukemia virus envelope (data not shown). Following infection
with VSV/HIV-1, a consistent but small percentage (⬍10%) of the
immature DCs expressed a green fluorescence protein reporter in
our HIV-1 plasmid (not shown). HIV-1 infection was monitored
by the production of reverse transcripts containing HIV-1 longterminal repeat and gag sequences; this production was sensitive to
pretreatment with AZT or 3TC (Fig. 1A). A vigorous infection
with VSV/HIV-1 was evident by the very high number of fulllength transcripts, ⬎104 for 2 ⫻ 104 cells (Fig. 1A). When analyzed by Western blot, the infected DCs expressed HIV-1 gag (Fig.
1B). As expected, VSV-G envelope expression was minimal because the pseudotyped virus should lack an envelope gene,
whereas DCs infected with wild-type VSV had readily detectable
G protein (Fig. 1C). When the infection of DCs was studied with
replicating, wild-type VSV, most of the cells were infected as detected by immunofluorescence with anti-VSV-G Ab (not shown),
again showing that most DCs were competent for entry via the
VSV envelope. These results show that VSV/HIV-1 efficiently infects immature DCs.
To monitor the production of viral protein and to assess the
effects of the VSV/HIV-1 on DC maturation, we cultured noninfected and infected immature DCs with the CD40L maturation
stimulus for 4 days and then used the FACS to measure p24 expression and various DC markers (CD83, CD25, CD86). As illustrated by the high expression of the CD86 costimulator, the presence of VSV/HIV-1 infection did not alter DC maturation
(compare the top and bottom rows of Fig. 1D). However, only
2–10% of the most mature DCs expressed p24. Although a higher
proportion of DCs might be infected and not be detected with the
current methods, it does appear that there is a block to the virus life
cycle in DCs, a block that occurs after reverse transcription. We
conclude that immature DCs can capture VSV-pseudotyped HIV-1
and then undergo maturation as well as expression of HIV-1 genes.

Enzyme-linked immunospot (ELISPOT) assay for IFN-␥ release
Ninety-six-well plates (Milliliter, Millipore, Bedford, MA) were coated
overnight at 4°C with 10 g/ml of anti-IFN-␥ mAb (Mabtech, Stockholm,
Sweden). The plates were washed and blocked with RPMI 1640/5% human
serum. PBMCs, or mixtures of DCs and T cells, infected or not with viral
vectors, were added to the coated plates for 36 h. The cells were lysed with
PBS/0.05% Tween 20, and the wells were incubated for 2 h with 1 g/ml
of biotin-conjugated, anti-IFN-␥ mAb (Mabtech). To visualize the spotforming foci (IFN-␥-secreting cells), the wells were washed and treated
with avidin HRP (Vectastain Elite kit; Vector Laboratories, Burlingame,
CA) followed by stable diaminobenzidine (Research Genetics, Huntsville,
AL) as substrate. The ELISPOT assay was also used to assess the expansion of Ag-specific T cells over time. DCs infected or not with VSV/HIV-1
were cocultured for 7 days with T cells. Then CD4 and CD8 cells were
purified and restimulated in the ELISPOT assay with monocytes infected
with vaccinia or avipox vectors or pulsed with 5 g/ml of either HIV-1 p24
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DCs were generated from the monocytes of normal donors and HIV-1infected individuals. CD14⫹ monocytes were positively selected from PBMCs using CD14 magnetic beads, as suggested by the vendor (Miltenyi
Biotec, Auburn, CA). A total of 1 ⫻ 106 CD14⫹ cells were plated in
six-well trays in 3 ml consisting of RPMI 1640 supplemented with 5%
human serum, recombinant human GM-CSF (100 IU/ml, Leukine; Immunex, Seattle, WA) and recombinant human IL-4 (1000 U/ml; Genzyme,
Cambridge, MA). The cells were fed on day 2 and 4 with 1 ml fresh
medium containing the same concentration of cytokines. At day 6, most of
the nonadherent cells were immature DCs, showing little or no expression
of the CD83, p55, DC-LAMP, and CD25 markers expressed by mature,
more stimulatory DCs. To promote maturation, we replated the nonadherent DCs at 106 cells/well for 4 days in 3 ml medium, supplemented with
cytokines as above and either LPS (Sigma, St. Louis, MO; 20 ng/ml) or
irradiated (3000 rad) CD40 ligand (CD40L)-transfected fibroblasts (a kind
gift of Dr. J. Banchereau, Baylor Institute for Immunology Research, Dallas, TX) at a ratio of 1 fibroblast to 7 DCs. In some experiments, soluble
CD40L was used. The CD14⫺ population was the source of T cells and was
kept frozen until use. In many experiments, CD14⫺ cells were separated by
nylon wool columns to obtain bulk T cells or by positive and negative
selection with CD4 and CD8 magnetic beads (Miltenyi Biotec).
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Ag PRESENTATION BY DC INFECTED WITH VSV/HIV-1

VSV/HIV-1-infected DCs present Ags to both CD4⫹ and CD8⫹
T cells

FIGURE 1. Expression of viral Ags in VSV/HIV-1-infected DCs. A,
Lysates from 2 ⫻ 104 immature noninfected DCs from a normal donor (n),
or from an infected patient (p), or from a VSV/HIV-1-infected patient
(pV/H) were amplified for early reverse transcripts (R/U5) and full-length
proviral DNA (LTR/gag) by PCR. In parallel, graded doses of ACH2 cells
were analyzed. In a separate experiment, patient DCs were infected with
virus after exposure or not to 1 M AZT or 3TC. B and C, Lysates of 104
293T cells and 105 immature DCs were infected or not with wild-type
VSV, VSV/HIV-1, and VSV/SIV and immunoblotted for gag (B) and
VSV-G (C) proteins. D, FACS analysis of HIV-1 p24 expression (x-axis)
and the CD86 costimulatory molecule (y-axis). Immature DCs were either
infected or not with VSV/HIV-1, and then each population was cultured
with the CD40L maturation stimulus for 4 more days. Arrows indicate the
p24 expressing DCs (3% in this experiment).

Mature DCs are more effective in HIV-1 Ag presentation than
immature DCs
We first tested the presentation of HIV-1 Ags by DCs that were
infected with nonreplicating virus and either kept in an immature

To identify subsets of T cells that could respond to the infected
DCs, CD4⫹ and CD8⫹ T cells were enriched either by positive or
negative selection using magnetic beads. T cell selections were
verified by FACS, and positively selected cells were found to be
98% enriched for the specific subset. The T cell subsets were then
stimulated for 36 h with autologous uninfected and VSV/HIV-1infected DCs in an IFN-␥ ELISPOT assay. As shown in Fig. 4A,
the CD8⫹ T cells were more active in the production of IFN-␥, but
in some patients the infected DCs could also stimulate IFN-␥ secretion from CD4⫹ cells (Fig. 4A). The number of T cells that
responded to DCs expressing HIV-1 Ags was high, 50 –200 cells
secreting IFN-␥ per 2 ⫻ 105 CD8⫹ cells. Comparable responses
were obtained when positively or negatively selected (CD8⫹ or
CD4⫺) populations were studied, ruling out an involvement of NK
cells in the IFN-␥ production. Nonetheless, in some cases we also
removed the CD56⫹ NK cells, which represented 1–5% of the
CD4⫺ cells, with CD56 beads, and this did not change the results
(data not shown). We conclude that VSV/HIV-1, a vector that is
reliably prepared to a high viral titer in a straightforward manner,
can be used to identify CD4⫹ and CD8⫹ T cells in HIV-1-infected
individuals on HAART (summarized in Table I).
Expansion of Ag-specific T cells with DCs infected with VSVpseudotyped HIV-1
We next tested whether infected DCs could expand Ag-specific T
cells in 5-day cultures. As in the case of the ELISPOT assay above
(Fig. 2), T cells from uninfected donors did not show proliferative
responses to autologous, VSV/HIV-1-infected DCs. In contrast,
CD8⫹ T cells from all patients proliferated in response to VSV/
HIV-1-infected DCs and did not show a significant syngeneic
MLR to uninfected DCs (Fig. 4B and Table I). At the DC:T ratios
that we used (1:10 –1:20), uninfected DCs did stimulate CD4⫹ T
cell proliferation, as a result of the syngeneic MLR, but in at least
half the patients studied, the infected DCs were further stimulatory
for CD4⫹ T cells (Fig. 4B and Table I). Therefore, VSV/HIV-1-
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state or allowed to mature. To study Ag presentation, DCs were
prepared from several HIV-1-infected individuals being followed
in two medical centers (Table I). CD14⫹ blood cells were cultured
in GM-CSF and IL-4 for 6 days and then infected with VSV/
HIV-1 or left noninfected. Then parallel aliquots were either kept
in cytokines (immature) or stimulated 4 days with CD40L to mature and express HIV-1 Ags. The DCs were added to autologous T
cells, and the response was measured in an IFN-␥ ELISPOT assay.
Mature infected DCs were much better stimulators of patient T
cells then immature infected DCs (Fig. 2; top, DCp and Tp). Noninfected DCs did not stimulate ELISPOT-producing T cells. Also,
the VSV/HIV-1-infected DCs from normal donors did not stimulate IFN-␥ release from autologous T cells (Fig. 2, DCn ⫹ Tn).
When patient DCs were infected with VSV/SIV, they failed to
stimulate T cells (not shown), indicating that the T cell response
was HIV-1 specific. In all four experiments of this kind, mature
DCs were better stimulators for autologous T cells than
immature DCs.
Several stimuli are known to induce DC maturation, such as the
inflammatory cytokines TNF-␣ and IL-1␤, LPS, monocyte-conditioned medium (MCM), and CD40L. Infected DCs matured with
CD40L were best able to present Ags to Ag-specific autologous T
cells relative to DCs matured with LPS (Fig. 3) and MCM (not
shown). Therefore, in all subsequent experiments, DCs were infected at the immature stage and matured with CD40L.
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Table I. DCs charged with VSV/HIV reliably stimulate CD4 and CD8 T cells
HIV
Therapy

Age

Sex

CD4

VL

1
2

40
37

M
M

900
385

ND
ND

3

52

F

540

ND

4

37

M

614

ND

AZT, 3TC
nelfinavir

5

50

M

501

ND

d4T, 3TC
saquinavir

6

34

F

380

ND

7

35

F

475

ND

d4T, 3TC
nevirapine
AZT, 3TC
nelfinavir

8

37

M

930

2,990

d4T, 3TC

9

48

F

419

2,297

10

35

M

285

⬍50

11

48

M

656

⬍50

d4T, 3TC
nelfinavir
AZT, 3TC
indinavir
d4T, 3TC
nelfinavir
d4T, 3TC
indinavir
d4T, 3TC

12

55

M

580

⬍50

13

38

M

604

13,140

14

51

M

664

⬍50

15

35

M

732

1,224

None
d4T, 3TC
nelfinavir
AZT, 3TC
nelfinavir

AZT
delavirdine
indinavir
d4T, 3TC
nelfinavir

ELISPOT
IFN-␥b

Prolifc

Bulk
Bulk

⫹⫹
⫺/⫹

ND
ND

Bulk
CD8⫺
CD8⫹
Bulk
CD4⫺
CD4⫹
CD8⫺
CD8⫹
Bulk
CD4⫹
CD4⫺
Bulk
CD8⫹
Bulk
CD4⫺
CD8⫺
CD4⫹
CD8⫹
CD4⫺
CD8⫺
PBMC

⫹⫹
⫹
⫹⫹
⫹⫹
⫹
⫹⫹
⫹
⫹⫹
⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫹
⫹
⫹⫹
⫹⫹
⫹⫹
⫹

⫺/⫹
⫹⫹
⫹
⫹
ND
⫹
⫹⫹
ND
ND
ND
ND
ND
⫹
⫺/⫹
ND
ND
⫹
⫹⫹
ND
ND
ND

CD4⫺

⫹

ND

CD4⫺

⫹

⫹

⫹

CD4
CD4⫺
CD4⫹
CD4⫺
CD4⫹
CD4⫺

⫹⫹
⫹⫹
⫹⫹
⫹⫹
⫺/⫹
⫹

⫺
ND
⫺/⫹
⫹
⫹
⫹

CD4⫹
CD8⫹
CD4⫺
CD8⫺

⫹
⫹⫹
⫹⫹
⫹

ND
ND
ND
ND

T Cells

a

Patients 1–7 were from institution 1 (Rockefeller University) and patients 8 –15 were from institution 2 (Mount Sinai School of Medicine).
Spots scored with stereo microscope. ⫹, 50 –100 spots; ⫹⫹, 100 –300 spots.
c
Proliferation determined by TdR incorporated in cell culture. ⫹, 10% of counts above background; ⫹⫹, 10 –50% of counts above background.
b

infected DCs can stimulate growth in CD4⫹ and CD8⫹ T cells
from HIV-1-primed donors.
To assess expansion of cytokine-producing effectors, we cocultured VSV/HIV-1-infected DCs for 7 days with autologous T cells.
The ELISPOT assay was then carried out using restimulation with
autologous monocytes pulsed with p24 or recombinant HIV-1 vectors. Fig. 5 shows a typical experiment in which T cells from an
individual donor were evaluated for IFN-␥ secretion in fresh bulk
PBMCs (Fig. 5A), in T cells stimulated with autologous DCs infected with various vectors (Fig. 5B), and with T cells expanded
for 7 days with DCs (Fig. 5C). It is evident that 1) VSV/HIV-1 is
not effective in fresh PBMCs (Fig. 5A), 2) VSV/HIV-1 is comparably effective to recombinant pox viral vectors when DCs are used
as APCs with fresh T cells (Fig. 5B), and 3) DCs infected with
VSV/HIV-1 clearly expand IFN-␥-secreting T cells, both CD4⫹
and CD8⫹ T cells (Fig. 5C).
Comparison of DCs and macrophages for presentation of VSV/
HIV-1 virus
We then set up dose response curves to compare the efficacy with
which DCs and macrophages, infected with pseudotyped HIV-1,
expand effector T cells. Mature DCs proved to be markedly more

potent. At a DC:T cell ratio of 1:30, the response was much greater
than macrophages at a ratio of 1:5, and at 1:30, macrophages had
no activity (Fig. 6). Taken together, the data on APC requirements
indicate that mature DCs should be targeted with nonreplicating
viral vectors to expand HIV-1 Ag-reactive T cells.
Endogenous and exogenous pathways for HIV-1 presentation by
infected DCs
We have shown above (Fig. 1A) that inhibitors of reverse transcription block the infection of DCs with VSV/HIV-1. To evaluate
the relative contributions of the endogenous (AZT-sensitive) and
exogenous (AZT-resistant) pathways of HIV-1 Ag presentation,
we conducted ELISPOT assays in which CD4⫹ and CD8⫹ cells
were stimulated with DCs that were treated with AZT. To block
endogenous presentation, we also studied envelope-deficient
HIV-1 particles produced by 293 cells in the absence of an env
plasmid. Fig. 7 shows that pretreatment of DCs with AZT substantially reduced IFN-␥ secretion by the CD8⫹ cells without affecting cytokine release by the CD4⫹ T cells. Similar results were
obtained when DCs were pretreated with 3TC, another reverse
transcriptase inhibitor (not shown). DCs infected with virus particles devoid of envelope also did not stimulate CD8⫹ T cells (Fig.
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FIGURE 2. Mature DCs present HIV-1 Ags more efficiently then immature DCs. Immature DCs were generated from normal individuals
(DCn) or from HIV-1 patients (DCp). The cells were infected or not with
VSV/HIV-1 and cultured without (immature) or with CD40L (mature) for
4 days. The different populations were used to stimulate autologous, nylon
wool-purified T cells in an ELISPOT assay at different DC:T ratios: 1:10 ⫽
1.5 ⫻ 104 DCs and 1.5 ⫻ 105 T cells; 1:20 ⫽ 7.5 ⫻ 103 DCs and 1.5 ⫻
105 T cells.

7). As in the case of DCs infected in the presence of AZT, DCs
pulsed with envelope-deficient virus were able to stimulate CD4⫹
T cells. Therefore, we conclude that VSV/HIV-1 charges MHC
class I molecules in DCs primarily by the endogenous pathway and
MHC II by an exogenous route.

to challenge with immunodeficiency viruses, HIV-1 and SIV.
Strong T cell immunity, comparable to that seen with immunogenic viruses, is not being observed when humans or monkeys are
vaccinated with current pox virus vectors.
Because mature DCs are not typically found in the periphery, we
assessed whether VSV/HIV-1 can be captured by immature DCs.
Whereas pox viruses have toxicity to immature DCs (32, 33) or
block their maturation (34), immature DCs allow nontoxic entry of
pseudotyped virus through the acid-sensitive VSV envelope. Interestingly, the level of full-length reverse transcripts is very high
(at least 104 copies in 2 ⫻ 104 DC in Fig. 1A), yet the percentage
of DCs expressing HIV-1 gag is relatively low (Fig. 1D), suggesting a block in the HIV-1 life cycle beyond reverse transcription.

Discussion
HIV-1 lacking its envelope gene and pseudotyped with other viral
envelopes, e.g., the G protein from VSV, has been useful for several studies of HIV-1 biology. Pseudotyped virus bypasses the normal CD4 and chemokine receptor entry mechanism required for
intact HIV-1 and also limits the ensuing infection to a single cycle.
Here we have studied Ag presentation of VSV-pseudotyped
HIV-1, which reverse transcribes to a high efficiency in DCs
(about 50%, Fig. 1A). However, VSV/HIV-1 expresses HIV-1 protein (but not VSV-G) in a small fraction of DCs (⬍10%, Fig. 1,
B–D). VSV-pseudotyped vectors are easy to prepare and, as long
as they are administered via mature DCs, prove to be very effective
at stimulating (Figs. 2, 3, and 4A) and expanding (Figs. 4B, 5, and
6) both CD4⫹ and CD8⫹ HIV-1-specific T cells. The VSVpseudotyped virus permits study of both exogenous and endogenous pathways of HIV-1 Ag presentation. Interestingly, one can
selectively present HIV-1 to CD4⫹ T cells using envelope-deficient HIV-1 particles from 293 producer cells (Fig. 7).
At this time, many nonreplicating forms of HIV-1 are being
considered as vaccine vectors, particularly avipox and modified
vaccine Ankara (see Ref. 31 for review). Our current studies are an
initial exploration of the use of VSV-pseudotyped virus to charge
DCs with HIV-1 Ags. We want to assess the hypothesis that targeting of a nonreplicating vaccine to mature DCs will enhance T
cell-mediated immunity and thereby provide an opportunity to
study the resistance that a well-primed T cell system can provide

FIGURE 4. VSV/HIV-1-infected DCs stimulate both CD4⫹ and CD8⫹
T cells. A, IFN-␥ release in ELISPOT assays by 1.5 ⫻ 105 positively and
negatively selected T cells stimulated with infected DCs derived from an
HIV-1 patient at a DC:T cell ratio of 1:10. B, Proliferative responses in
identical cultures as A, but assessed after 5 days by pulsing the cultures for
8 h with 1 Ci of [3H]thymidine.
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FIGURE 3. Effect of maturation stimuli on HIV-1 Ag presentation by
DCs infected as immature cells. Immature DCs were generated with GMCSF and IL-4 from the blood of HIV-1 patients and infected at day 6 with
VSV/HIV-1. The cells were matured with LPS (20 ng/ml) or irradiated
CD40L-transfected fibroblasts (1 CD40L cell for 7 DCs). After 4 days,
DCs were added to T cells to stimulate the release of IFN-␥ as measured
by ELISPOT.
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FIGURE 5. Expansion of effector cells by DCs infected with VSV/
HIV-1. Effector cells were measured in the same patient under various
conditions using an ELISPOT assay for IFN-␥-secreting cells. A, PBMCs,
or PBMCs depleted of CD8 cells, were infected with different vectors, and
ELISPOTs were measured 36 h later. B, Same as A, but now bulk
CD4⫹and CD8⫹ T cells were stimulated with DCs infected with the indicated vectors at a DC:T ratio of 1:10. Mature DCs were used for the
vaccina and avipox infections. C, DCs, without or with infection with
VSV/HIV-1, were used to expand T cells in a 7-day culture. Then
CD4⫹and CD8⫹ T cells were prepared and restimulated with monocytes
pulsed with p24 protein, control protein, or recombinant avipox and vaccinia HIV-1.

Although our current studies exploit the VSV-G as the entry mechanism, additional uptake receptors are known to be expressed by
DCs. These include the macrophage mannose receptor (35) and
DEC-205 (36), both multilectin receptors for adsorptive endocytosis. Other newly recognized C-type lectins, Langerin (37) and
DC-SIGN (38), are not yet known to lead to Ag presentation.
Following uptake into immature DCs, the cells could be induced
to mature and became more potent in presenting HIV-1 Ags (Figs.
2 and 3). We tested several maturation stimuli and found CD40L
to be superior to LPS and MCM. Together, our data indicate that
a nonreplicating vaccine can be captured by immature DCs, and
then maturation harnesses the T cell stimulatory potential of
these APCs.
There are interesting advantages to the use of pseudotyped virus
for delivering HIV-1 Ags to the immune system in vivo. The first
is safety. The virus is not pathogenic, because it is genetically
unable to undergo more than a single cycle of replication. We have
verified this previously by showing that pseudotyped virus is not

transmitted from DCs to T cells, as occurs with wild-type HIV-1
(24), nor does the virus replicate in DCs cultured for up to 7 days.
A second advantage is the ease of preparation. High titer virus
(10 6–107 infectious units/ml in the Magi assay) is produced by
simple cotransfection of the 293 T producer line with the VSV-G
and env-deficient HIV-1 plasmids. Third, as discussed above,
VSV-pseudotyped virus gains access to immature DCs, which are
rich in acidic, endocytic compartments and represent the most logical sites for capture of vaccines in vivo (9, 10). Fourth, antienvelope Abs should not be induced when pseudotyped viruses are
targeted to DCs. VSV-G is poorly expressed in the infected DCs,
so B cells should not be selected to produce anti-envelope Abs.
Moreover, most humans do not have preexisting neutralizing Abs
to VSV. A fifth advantage, and the emphasis of this paper, is that

FIGURE 7. Endogenous and exogenous pathways for presentation of
VSV/HIV-1 by DCs. Immature DCs from an HIV-1-infected patient were
pretreated with 1 M AZT for 1 h and then infected with VSV/HIV-1.
HIV-1 particles without envelope were also used. DCs were added to 2 ⫻
105 bulk CD4⫹ or CD8⫹ T cells, and IFN-␥ release was assayed after 36 h.
Where indicated, AZT was present throughout the culture.
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FIGURE 6. Comparison of DCs and macrophages for HIV-1 Ag presentation. Macrophages and DCs were generated from an HIV-1-infected
patient, infected with VSV/HIV-1 at day 6, and kept in culture for 4 days.
The DCs were matured with CD40L cells. Both types of APC were assessed for their T cell stimulatory capacity in ELISPOT assay at different
APC:T ratios (constant numbers, 5 ⫻ 105, of T cells). Similar results were
obtained with cells prepared from different patients.
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VSV/HIV-1 is efficiently presented to both CD4⫹ and CD8⫹ T
cells by DCs. Both CD4⫹ and CD8⫹ subsets are probably required
for strong T cell memory and protection against HIV-1 (39 – 41).
In fact, DCs charged with VSV/HIV-1 induce robust T cell responses from primed T cells, both in terms of the absolute number
of IFN-␥-secreting cells and the high levels of DNA synthesis,
especially in CD8⫹ cells.
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